Propel Bio Management, LLC 13F holdings, Q1 2026
Holdings as of March 31, 2026 · filings on SEC EDGAR · latest filing →
Propel Bio Management, LLC disclosed 38 US equity positions worth $158.7m in its Q1 2026 13F filing. The largest position was PAGPEUR at 19.0% of the reported book, followed by ACHV and PHAT.
What did Propel Bio Management, LLC own in Q1 2026? Top 38 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs prior |
|---|---|---|---|---|---|---|---|
| 1 | PAGPEUR PLAINS GP HLDGS L P | 19.0% | $30.2m | 1,272,360 | – | ||
| 2 | ACHV ACHIEVE LIFE SCIENCES INC | 7.2% | $11.4m | 3,786,425 | – | ||
| 3 | PHAT PHATHOM PHARMACEUTICALS INC | Healthcare | 5.9% | $9.4m | 841,272 | – | |
| 4 | DCTH DELCATH SYS INC | 5.8% | $9.2m | 979,698 | – | ||
| 5 | CORT CORCEPT THERAPEUTICS INC | Healthcare | 3.8% | $6.0m | 147,828 | – | |
| 6 | ABEO ABEONA THERAPEUTICS INC | Healthcare | 3.8% | $6.0m | 1,329,899 | – | |
| 7 | VOR VOR BIOPHARMA INC | Healthcare | 3.5% | $5.6m | 314,543 | – | |
| 8 | KYTX KYVERNA THERAPEUTICS INC | 3.5% | $5.6m | 644,421 | – | ||
| 9 | MIST MILESTONE PHARMACEUTICALS IN | 3.2% | $5.1m | 4,118,321 | – | ||
| 10 | CLDX CELLDEX THERAPEUTICS INC NEW | Healthcare | 2.6% | $4.1m | 131,364 | – | |
| 11 | CMPS COMPASS PATHWAYS PLC | Healthcare | 2.6% | $4.1m | 742,049 | – | |
| 12 | VRDN VIRIDIAN THERAPEUTICS INC | Healthcare | 2.6% | $4.1m | 210,163 | – | |
| 13 | IVA INVENTIVA SA | 2.5% | $4.0m | 724,678 | – | ||
| 14 | SABS SAB BIOTHERAPEUTICS INC | 2.4% | $3.9m | 1,012,790 | – | ||
| 15 | OBIO ORCHESTRA BIOMED HLDGS INC | 2.4% | $3.8m | 896,701 | – | ||
| 16 | FDMT 4D MOLECULAR THERAPEUTICS IN | Healthcare | 2.3% | $3.6m | 380,420 | – | |
| 17 | OCULIS HOLDING AG | 2.1% | $3.3m | 122,223 | – | ||
| 18 | OCUL OCULAR THERAPEUTIX INC | Healthcare | 2.0% | $3.2m | 382,375 | – | |
| 19 | UPB UPSTREAM BIO INC | 2.0% | $3.1m | 341,779 | – | ||
| 20 | AQST AQUESTIVE THERAPEUTICS INC | 1.9% | $3.0m | 710,988 | – | ||
| 21 | EYPT EYEPOINT INC | Healthcare | 1.8% | $2.8m | 215,825 | – | |
| 22 | TRVI TREVI THERAPEUTICS INC | Healthcare | 1.7% | $2.6m | 223,802 | – | |
| 23 | ZVRA ZEVRA THERAPEUTICS INC | 1.7% | $2.6m | 282,418 | – | ||
| 24 | IMUX IMMUNIC INC | Healthcare | 1.7% | $2.6m | 2,344,779 | – | |
| 25 | CHRS COHERUS ONCOLOGY INC | Healthcare | 1.5% | $2.4m | 1,420,550 | – | |
| 26 | OVID OVID THERAPEUTICS INC | Healthcare | 1.3% | $2.0m | 921,457 | – | |
| 27 | PALI PALISADE BIO INC | Healthcare | 1.3% | $2.0m | 1,115,000 | – | |
| 28 | KLRS KALARIS THERAPEUTICS INC | 1.1% | $1.7m | 295,771 | – | ||
| 29 | UNIQURE NV | 1.1% | $1.7m | 104,772 | – | ||
| 30 | LONA LEONABIO INC | 0.9% | $1.5m | 149,279 | – | ||
| 31 | NUVB NUVATION BIO INC | Healthcare | 0.9% | $1.4m | 329,296 | – | |
| 32 | MAZE MAZE THERAPEUTICS INC | Healthcare | 0.8% | $1.3m | 43,798 | – | |
| 33 | EVMN EVOMMUNE INC | 0.8% | $1.3m | 55,664 | – | ||
| 34 | CRVS CORVUS PHARMACEUTICALS INC | Healthcare | 0.8% | $1.3m | 85,791 | – | |
| 35 | ALDX ALDEYRA THERAPEUTICS INC | Healthcare | 0.8% | $1.2m | 730,606 | – | |
| 36 | ARTV ARTIVA BIOTHERAPEUTICS INC | 0.6% | $949.8k | 146,369 | – | ||
| 37 | CNTB CONNECT BIOPHARMA HLDGS LTD | 0.3% | $553.9k | 209,493 | – | ||
| 38 | MSLE SATELLOS BIOSCIENCE INC | 0.0% | $57.1k | 10,145 | – |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.